Tocilizumab for the treatment of adult-onset Still’s disease

References

• Magadur-Joly G, Billaud E, Barrier JH, et al. Epidemiology of adult Still’s disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis. 1995;54:587–590.
   PubMed Web of Science ®Google Scholar
• Evensen KJ, Nossent HC. Epidemiology and outcome of adult-onset Still’s disease in Northern Norway. Scand J Rheumatol. 2006;35:48–51.
   PubMed Web of Science ®Google Scholar
• Castañeda S, Blanco R, González-Gay MA. Adult-onset Still’s disease: advances in the treatment. Best Pract Res Clin Rheumatol. 2016;30:222–238.
   PubMed Web of Science ®Google Scholar
• Sampalis JS, Esdaile JM, Medsger TA Jr, et al. A controlled study of the long-term prognosis of adult Still’s disease. Am J Med. 1995;98:384–388.
   PubMed Web of Science ®Google Scholar
• Cagatay Y, Gul A, Cagatay A, et al. Adult-onset Still’s disease. Int J Clin Pract. 2009;63:1050–1055.
   PubMed Web of Science ®Google Scholar
• Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell. 2010;140:784–790.
   PubMed Web of Science ®Google Scholar
• Cush JJ. Autoinflammatory syndromes. Dermatol Clin. 2013;31:471–480.
   PubMed Web of Science ®Google Scholar
• Nirmala N, Brachat A, Feist E, et al. Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol Online J. 2015;13:50.
   PubMed Web of Science ®Google Scholar
• Inoue N, Shimizu M, Tsunoda S, et al. Cytokine profile in adult-onset Still’s disease: comparison with systemic juvenile idiopathic arthritis. Clin Immunol. 2016;169:8–13.
   PubMed Web of Science ®Google Scholar
• Jamilloux Y, Gerfaud-Valentin M, Martinon F, et al. Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart. Immunol Res. 2015;61:53–62.
   PubMed Web of Science ®Google Scholar
• Giampietro C, Fautrel B. Anti-interleukin-1 agents in adult onset Still’s disease. Int J Inflam. 2012;2012:317820.
   PubMedGoogle Scholar
• Iliou C, Papagoras C, Tsifetaki N, et al. Adult-onset Still’s disease: clinical, serological and therapeutic considerations. Clin Exp Rheumatol. 2013;31:47–52.
   PubMed Web of Science ®Google Scholar
• Castañeda S, Vicente EF, González-Gay MA. [Adult-onset Still’s disease]. Med Clin (Barc). 2016;147: 217–222. Review. Spanish.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Le Moël G, Saint-Marcoux B, et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still’s disease. J Rheumatol. 2001;28:322–329.
   PubMed Web of Science ®Google Scholar
• Vignes S, Le Moël G, Fautrel B, et al. Percentage of glycosylated serum ferritin remains low throughout the course of adult onset Still’s disease. Ann Rheum Dis. 2000;59:347–350.
   PubMed Web of Science ®Google Scholar
• Maria AT, Le Quellec A, Jorgensen C, et al. Adult onset Still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev. 2014;13:1149–1159.
   PubMed Web of Science ®Google Scholar
• Cabane J, Michon A, Ziza JM, et al. Comparison of long-term evolution of adult onset and juvenile onset Still’s disease, both followed up for more than10 years. Ann Rheum Dis. 1990;49:283–285.
   PubMed Web of Science ®Google Scholar
• Kong XD, Xu D, Zhang W, et al. Clinical features and prognosis in adult-onset Still’s disease: a study of 104 cases. Clin Rheumatol. 2010;29:1015–1019.
   PubMed Web of Science ®Google Scholar
• Gerfaud-Valentin M, Jamilloux Y, Iwaz J, et al. Adult-onset Still’s disease. Autoimmun Rev. 2014;13:708–722.
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Kadavath S, Mehta B. Life-threatening complications of adult-onset Still’s disease. Clin Rheumatol. 2014;33:305–314.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Cipriani P, Ciccia F, et al. Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: analysis of 41 cases collected in 2 rheumatologic centers. Autoimmun Rev. 2017;16:16–21.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Iacono D, Ciccia F, et al. Macrophage activation syndrome in patients affected by adult-onset Still disease: analysis of survival rates and predictive factors in the Gruppo Italiano di Ricerca in reumatologia clinica e sperimentale cohort. J Rheumatol. 2018;45:864–872.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Cipriani P, Di Benedetto P, et al. Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? Expert Rev Clin Immunol. 2017;13:1041–1047.
   PubMed Web of Science ®Google Scholar
• Franchini S, Dagna L, Salvo F, et al. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still’s disease. Arthritis Rheum. 2010;62:2530–2535.
   PubMed Web of Science ®Google Scholar
• Gerfaud-Valentin M, Maucort-Boulch D, Hot A, et al. Adult-onset Still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93:91–99.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Borget C, Rozenberg S, et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still’s disease. J Rheumatol. 1999;26:373–378.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Sibilia J, Mariette X, et al.; Club Rhumatismes et Inflammation. Tumour necrosis factor alpha blocking agents in refractory adult Still’s disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64:262–266.
   PubMed Web of Science ®Google Scholar
• Pouchot J, Arlet J-B. Biological treatment in adult-onset Still’s disease. Best Pract Res Clin Rheumatol. 2012;26:477–487.
   PubMed Web of Science ®Google Scholar
• Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol. 2018;14:603–618.
   PubMed Web of Science ®Google Scholar
• Puéchal X, DeBandt M, Berthelot J-M, et al. Tocilizumab in refractory adult Still’s disease. Arthritis Care Res (Hoboken). 2011;63:155–159.
   PubMed Web of Science ®Google Scholar
• Nishina N, Kaneko Y, Kameda H, et al. The effect of tocilizumab on preventing relapses in adult-onset Still’s disease: a retrospective, single-center study. Mod Rheumatol. 2015;25:401–404.
   PubMed Web of Science ®Google Scholar
• Yoo DH. Treatment of adult-onset Still’s disease: up to date. Expert Rev Clin Immunol. 2017;13:849–866.
   PubMed Web of Science ®Google Scholar
• Ma Y, Wu M, Zhang X, et al. Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still’s disease: a meta-analysis. Mod Rheumatol. 2018;28:849–857.
   PubMed Web of Science ®Google Scholar
• Asanuma YF, Mimura T, Tsuboi H, et al. Nationwide epidemiological survey of 169 patients with adult Still’s disease in Japan. Mod Rheumatol. 2015;25:393–400.
   PubMed Web of Science ®Google Scholar
• Kalyoncu U, Solmaz D, Emmungil H, et al. Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still’s disease: data from a large multicenter cohort. J Autoimmun. 2016;69:59–63.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Cipriani P, Masedu F, et al. Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med. 2016;14:194.
   PubMed Web of Science ®Google Scholar
• Sfriso P, Priori R, Valesini G, et al. Adult-onset Still’s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clin Rheumatol. 2016;35:1683–1689.
   PubMed Web of Science ®Google Scholar
• Castañeda S, Atienza-Mateo B, Martín-Varillas JL, et al. Anakinra for the treatment of adult-onset Still’s disease. Expert Rev Clin Immunol. 2018;14:979–992.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424–430.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Zing E, Golmard JL, et al. Proposal for a new set of classification criteria for adult-onset Still disease. Medicine (Baltimore). 2002;81:194–200.
   PubMed Web of Science ®Google Scholar
• Ciprani P, Ruscitti P, Carubbi F, et al. Tocilizumab for the treatment of adult-onset Still’s disease: results from a case series. Clin Rheumatol. 2014;33:49–55.
   PubMed Web of Science ®Google Scholar
• Kadavath S, Efthimiou P. Adult-onset Still’s disease-pathogenesis, clinical manifestations, and new treatment options. Ann Med. 2015;47:6–14.
   PubMed Web of Science ®Google Scholar
• Elkayam O, Jiries N, Dranitzki Z, et al. Tocilizumab in adult-onset Still’s disease: the Israeli experience. J Rheumatol. 2014;41:244–247.
   PubMed Web of Science ®Google Scholar
• Alten R, Maleitzke T. Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases. Ann Med. 2013;45:357–363.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–2395.
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, et al. Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan. Ann Rheum Dis. 2013;72:627–628.
   PubMed Web of Science ®Google Scholar
• Roactemra, INN-tocilizumab-European Medicines Agency-Europa EU: summary of product characteristics. [ cited 2018 Aug 12]. Available from: https://www.ema.europa.eu/documents/product-information/roactemra-epar-product-information_en.pdf
   Google Scholar
• Kim S, Östör AJ, Nisar MK. Interleukin-6 and cytochrome-P450, reason for concern? Rheumatol Int. 2012;32:2601–2604.
   PubMed Web of Science ®Google Scholar
• Schmitt C, Kuhn B, Zhang X, et al. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89:735–740.
   PubMed Web of Science ®Google Scholar
• Ortiz-Sanjuán F, Blanco R, Calvo-Rio V, et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still’s disease: multicenter retrospective open-label study of thirty-four patients: tocilizumab in AOSD refractory to standard treatment. Arthritis Rheumatol. 2014;66:1659–1665.
   PubMed Web of Science ®Google Scholar
• Song ST, Kim JJ, Lee S, et al. Efficacy of tocilizumab therapy in Korean patients with adult-onset Still’s disease: a multicentre retrospective study of 22 cases. Clin Exp Rheumatol. 2016;34(6 Suppl 102):S64–S71.
   PubMed Web of Science ®Google Scholar
• Suematsu R, Ohta A, Matsuura E, et al. Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan. Mod Rheumatol. 2012;22(5):712–719.
   PubMed Web of Science ®Google Scholar
• Takakuwa Y, Ooka S, Ito H, et al. Efficacy and safety of biologic agents for the treatment of refractory adult Still’s disease. Abstract Supplement Eular 2013 Annual European Congress of Rheumatol. Ann Rheum Dis. 2013;72(Suppl3):329. Abstract Number THU0488.
   PubMedGoogle Scholar
• Kaneko Y, Kameda H, Ikeda K, et al. Tocilizumab in patients with adult-onset Still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis. 2018;77:1720–1729.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Na KS, Kim TH, et al. Pilot trial of tocilizumab for refractory patients with adult onset Still’s disease. Abstract Supplement EULAR 2013 Annual European Congress of Rheumatol. Ann Rheum Dis. 2013;72(Suppl3):322. Abstract Number THU0466.
   PubMedGoogle Scholar
• Kondo T, Okada Y, Shibata A, et al. Corticosteroid-free tocilizumab monotherapy for adult onset Still’s disease: results in six month. Abstract Supplement 2016 ACR/ARHP Annual Meeting. Arthritis Rheumatol. 2016;68(Suppl10). Abstract Number 253.
   Google Scholar
• Li T, Gu L, Wang X, et al. A pilot study on tocilizumab for treating refractory adult-onset Still’s disease. Sci Rep. 2017;7:13477.
   PubMed Web of Science ®Google Scholar
• Muraviev Y, Podryadnova M, Nasanov E. Experience of tocilizumab using for resistant adult-onset Still’s disease. Abstract Supplement EULAR 2012 Annual European Congress of Rheumatol. Ann Rheum Dis. 2012;71(Suppl3). Abstract Number AB0588.
   Google Scholar
• Kim JJ, Joo YB, Yoo DH. Treatment trend of biologic agents in Korean patients with adult onset Still’s disease. Abstract Supplement EULAR 2014 Annual European Congress of Rheumatol. Ann Rheum Dis. 2014;73(Suppl2): 314. Abstract Number THU0384.
   Google Scholar
• Bannai E, Yamashita H, Kaneko S, et al. Successful tocilizumab therapy in seven patients with refractory adult-onset Still’s disease. Mod Rheumatol. 2016;26:297–301.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Franchini S, Aiello P, et al. Efficacy and safety of biological agents in adult-onset Still’s disease. Scand J Rheumatol. 2015;44:309–314.
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Nara H, Hirata D, et al. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still’s disease. Arthritis Rheum. 2002;46:3388–3389.
   PubMed Web of Science ®Google Scholar
• Rech J, Ronneberger M, Englbrecht M, et al. Successful treatment of adult-onset Still’s disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade. Ann Rheum Dis. 2011;70:390–392.
   PubMed Web of Science ®Google Scholar
• Thonhofer R, Hiller M, Just H, et al. Treatment of refractory adult-onset Still’s disease with tocilizumab: report of two cases and review of the literature. Rheumatol Int. 2011;31:1653–1656.
   PubMed Web of Science ®Google Scholar
• Pettinari L, Gentile A, Gambini S, et al. Preliminary report on the effectiveness of tocilizumab in Still disease. Clin Exp Rheumatol. 2011;29:213–214.
   Web of Science ®Google Scholar
• Sakai R, Shibata A, Chino K, et al. The efficacy of tocilizumab for adult-onset Still’s disease. Int J Rheum Dis. 2012;15(suppl 1):125.
   Google Scholar
• Sato K, Yamamoto A, Yoshida Y, et al. Two cases of multiple-drug-resistant adult-onset Still’s disease treated successfully with tocilizumab - the relationship between interleukin 6 and 18. Arthritis Res Ther. 2012;14(suppl 1):46.
   Google Scholar
• Sakai R, Nagasawa H, Nishi E, et al. Successful treatment of adult-onset Still’s disease with tocilizumab monotherapy: two case reports and literature review. Clin Rheumatol. 2012;31:569–574.
   PubMed Web of Science ®Google Scholar
• De Boysson H, Fevrier J, Nicolle A, et al. Tocilizumab in the treatment of the adult-onset Still’s disease: current clinical evidence. Clin Rheumatol. 2013;32:141–147.
   PubMed Web of Science ®Google Scholar
• Kobayashi D, Ito S, Murasawa A, et al. Two cases of adult-onset Still’s disease treated with tocilizumab that achieved tocilizumab-free remission. Intern Med. 2015;54:2675–2679.
   PubMed Web of Science ®Google Scholar
• Dall’Ara F, Frassi M, Tincani A, et al. A retrospective study of patients with adult-onset Still’s disease: is pericarditis a possible predictor for biological disease-modifying anti-rheumatic drugs need? Clin Rheumatol. 2016;35:2117–2123.
   PubMed Web of Science ®Google Scholar
• Savage E, Wazir T, Drake M, et al. Fulminant myocarditis and macrophage activation syndrome secondary to adult-onset Still’s disease successfully treated with tocilizumab. Rheumatology (Oxford). 2014;53:1352–1353.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Takahashi Y, Yamashita H, et al. Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 2011;21:92–96.
   PubMed Web of Science ®Google Scholar
• Kadavath S, Zapantis E, Zolty R, et al. A novel therapeutic approach in pulmonary arterial hypertension as a complication of adult-onset Still’s disease: targeting IL-6. Int J Rheum Dis. 2014;17:336–340.
   PubMed Web of Science ®Google Scholar
• García-Gómez C, Martín-Martínez MA, Castañeda S, et al.; CARMA Project Collaborative Group. Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: results from the cardiovascular in rheuMAtology study project. J Clin Lipidol. 2017;11:749–756.e3.
   PubMed Web of Science ®Google Scholar
• Tsuchida Y, Sumitomo S, Shoda H, et al. Macrophage activation syndrome associated with tocilizumab treatment in adult-onset Still’s disease. Mod Rheumatol. 2017;27:556–557.
   PubMed Web of Science ®Google Scholar
• Amenomori M, Migita K, Miyashita T, et al. Cytomegalovirus-associated hemophagocytic syndrome in a patient with adult onset Still’s disease. Clin Exp Rheumatol. 2005;23:100–102.
   PubMed Web of Science ®Google Scholar
• Altinok G, Levine M, Dhar JP, et al. Successful tocilizumab therapy in seven patients with refractory adult-onset Still’s disease. Case Rep Rheumatol. 2016;26:297–301.
   Google Scholar
• Shimizu M, Nakagishi Y, Kasai K, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin 18 and interleukin-6. Cytokine. 2012;58:287–294.
   PubMed Web of Science ®Google Scholar
• Watanabe E, Sugawara H, Yamashita T, et al. Successful tocilizumab therapy for macrophage activation syndrome associated with adult-onset Still’s disease: a case-based review. Case Rep Med. 2016;2016:5656320.
   PubMed Web of Science ®Google Scholar
• Yokota S, Itoh Y, Morio T, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab. J Rheumatol. 2015;42:712–722.
   PubMed Web of Science ®Google Scholar
• Fitzgerald JC, Weiss SL, Maude SL, et al. Cytokine release syndrome after chimeric antigen receptor t cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45:e124–e131.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–1517.
   PubMed Web of Science ®Google Scholar
• Fujii T, Nojima T, Yasuoka H, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still’s disease. Association with chronic articular disease. Rheumatology (Oxford). 2001;40:1398–1404.
   PubMed Web of Science ®Google Scholar
• Chen D-Y, Lan J-L, Lin F-J, et al. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol. 2004;31:2189–2198.
   PubMed Web of Science ®Google Scholar
• Gerfaud-Valentin M, Sève P, Hot A, et al. [Pathophysiology, subtypes, and treatments of adult-onset Still’s disease: an update]. Rev Med Interne. 2015;36:319–327.
   PubMed Web of Science ®Google Scholar
• García-Porrúa C, González-Juanatey C, González-Gay MA. Endocarditis in adult onset Still’s disease: a 12 month followup. J Rheumatol. 2001;28:2141–2142.
   PubMed Web of Science ®Google Scholar
• Stoffels M, Jongekrijg J, Remijn T, et al. TLR2/TLR4-dependent exaggerated cytokine production in hyperimmunoglobulinaemia D and periodic fever syndrome. Rheumatology (Oxford). 2015;54:363–368.
   PubMed Web of Science ®Google Scholar
• La Torre F, Muratore M, Vitale A, et al. Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Rheumatol Int. 2015;35:1943–1947.
   PubMed Web of Science ®Google Scholar
• Yao Q, Shen B. A systematic analysis of treatment and outcomes of nod2- associated autoinflammatory disease. Am J Med. 2017;130:365.e13–365.e18.
   PubMed Web of Science ®Google Scholar
• Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L, et al. Efficacy of anakinra in refractory adult-onset Still’s disease: multicenter study of 41 patients and literature review. Medicine (Baltimore). 2015;94(39):e1554.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Ursini F, Cipriani P, et al. Biologic drugs in adult onset Still’s disease: a systematic review and meta-analysis of observational studies. Expert Rev Clin Immunol. 2017;13:1089–1097.
   PubMed Web of Science ®Google Scholar
• Girard C, Rech J, Brown M, et al. Elevated serum levels of free interleukin-18 in adult-onset Still’s disease. Rheumatology (Oxford). 2016;55:2237–2247.
   PubMed Web of Science ®Google Scholar
• Mitrovic S, Fautrel B. New markers for adult-onset Still’s disease. Joint Bone Spine. 2018;85:285–293.
   PubMed Web of Science ®Google Scholar
• Gabay C, Fautrel B, Rech J, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis. 2018;77:840–847.
   PubMed Web of Science ®Google Scholar
• Kiltz U, Kiefer D, Braun J, et al. Prolonged treatment with tadekinig alfa in adult-onset Still’s disease. Ann Rheum Dis. 2018 Oct 23;pii: annrheumdis-2018-214496. DOI:10.1136/annrheumdis-2018-214496
   Web of Science ®Google Scholar